Tumor cells resistant to GDC-0941, a PI3K inhibitor, exhibit an increased activation of the PI3K/AKT/mTOR signaling pathway and OGT expression in comparison to GDC-0941-sensitive cells. This evidence concerns the gene AKT1 and neoplasm.